Myriad launches BRACAnalysis BRCA1/BRCA2 cancer predisposition testing service.
This article was originally published in The Gray Sheet
MYRIAD LAUNCHES BRACANALYSIS GENETIC TESTING SERVICE for predisposition to breast and ovarian cancer on Oct. 30. The test uses DNA sequencing to identify mutations in the BRCA1 and BRCA2 genes, which Myriad Genetics says are responsible for approximately 90% of all early onset hereditary breast and ovarian cancers.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.